Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922207 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL28603730 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL6246216 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL11570348 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL11708766 | 0.87 | TSHR (0.43) | TSHRALDH1A1TP53 | |
| SCHEMBL25841567 | 0.86 | ALDH1A1 (0.44) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL56801 | 0.85 | — | — | |
| SCHEMBL28616847 | 0.83 | ALDH1A1 (0.50) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL31665165 | 0.82 | TSHR (0.50) | TSHRALDH1A1TP53 | |
| SCHEMBL13863435 | 0.81 | ADRA2A (0.41) | TSHRCA2ALDH1A1TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-06-26 | — | — | US | disclosed |
| US-11998611-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2024-06-04 | — | — | US | disclosed |
| US-20210228726-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2021-07-29 | — | — | US | disclosed |
| US-20210228726-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2021-07-29 | — | — | US | disclosed |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2021-05-18 | — | — | US | disclosed |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20200093934-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2020-03-26 | — | — | US | disclosed |
| EP-3621658-A1 | PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, USEFUL IN THERAPY, AND THEIR PREPARATION | Sanofi (FR) | 2020-03-18 | — | — | EP | disclosed |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-02-20 | — | — | US | disclosed |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-02-20 | — | — | US | disclosed |
| US-20180369401-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2018-12-27 | — | — | US | disclosed |
| WO-2018206635-A1 | PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, USEFUL IN THERAPY, AND THEIR PREPARATION | SANOFI (FR) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998611-B2 | Cryptophycin antibody conjugates for the treatment of cancer | CLSPN, HCCS, INCENP | TSHR 4402/4885CA2 1651/4885ALDH1A1 2828/4885 |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | XPOT, CHMP4B, XPO5 | TSHR 4421/4885CA2 1184/4885ALDH1A1 2273/4885 |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | TSHR 4462/4885CA2 2460/4885ALDH1A1 3013/4885 |
| US-20200093934-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | TSHR 4462/4885CA2 2460/4885ALDH1A1 3013/4885 |
| US-20180369401-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | TSHR 4462/4885CA2 2460/4885ALDH1A1 3013/4885 |
| US-20210228726-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | TSHR 4462/4885CA2 2460/4885ALDH1A1 3013/4885 |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | RPN1, CLSPN, FRG1 | TSHR 4489/4885CA2 2417/4885ALDH1A1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.